The grants for the development of Clinical Research Units within the framework of the PERTE for Cutting-Edge Health, in its 2024 edition, are an initiative of the Ministry of Science, Innovation, and Universities managed through the Carlos III Health Institute (ISCIII). This action is aimed at the creation and strengthening of patient-oriented Clinical Research Units.
Endowed with 45 million euros, this call is part of Component 17 of the Recovery, Transformation, and Resilience Plan called “Institutional Reform and Strengthening of the National System of Science, Technology, and Innovation”. These grants are included in the PERTE for Cutting-Edge Health and align with several of the strategic objectives of the State Plan for Scientific, Technical, and Innovative Research (PEICTI).
The main objective of the call is to improve the prevention, diagnosis, treatment, and rehabilitation of patients in the National Health System through the promotion of precision medicine, advanced therapies, and artificial intelligence. The action is aimed at addressing health challenges faced by the population through the strengthening of scientific and healthcare institutions, especially in territories with lower development of these capacities.
Furthermore, the call focuses on providing adequate coverage of the needs of patients participating in clinical trials and their families, with special attention to vulnerable groups. It also considers strengthening clinical research in less developed geographical areas in this field, which will promote access to clinical trials for the population in these areas, consolidating Spain’s position as the second country in the world in clinical trial development and improving the research capabilities of the National Health System.
The grants are aimed at public health entities and institutions with clinical care activity, such as hospitals, primary care centers, and other healthcare facilities with health licenses. The condition of being a public sector entity will be accredited by confirming the presence of the applicant entity in the Inventory of State, Regional, and Local Public Sector Entities.
The maximum amount allocated for the grants is 45 million euros from the Recovery and Resilience Mechanism and will be granted in the form of subsidies. The amount of the subsidy will be determined based on the evaluation and selection criteria applied according to the type of grant and based on criteria for maximum efficiency in the allocation of available economic resources. Selected projects may be co-financed by the applicant and beneficiary entity with its own funds or funds from other sources.
Applications must be submitted through the electronic headquarters of the Carlos III Health Institute. The deadline for submitting applications is from July 16 to September 12, 2024.
The PERTE for Cutting-Edge Health is one of the 12 strategic projects for the economic recovery and transformation of the Recovery, Transformation, and Resilience Plan. Its objective is to develop innovative procedures to improve the prevention, diagnosis, treatment, or rehabilitation of patients in a personalized manner, using medications or advanced therapies. Its purpose is to transform the healthcare sector with actions where science, innovation, and digitalization act as a lever to address new health challenges.
At the time of designing this strategic project, an investment of 1,469 million euros from the public and private sectors was planned for the period 2021-2023. Subsequently, with the adoption of the addendum in the fall of 2023, the implementation of the actions has been extended until 2026, and the investment amount has been increased to 2,358.61 million euros including public and private investment.
Referrer: MiMub in Spanish
